Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ. de Bruin RC, et al. Among authors: van der vliet hj, van bergen en henegouwen pm. J Immunol. 2017 Jan 1;198(1):308-317. doi: 10.4049/jimmunol.1600948. Epub 2016 Nov 28. J Immunol. 2017. PMID: 27895170
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM. Roovers RC, et al. Among authors: van dongen ga, van bergen en henegouwen pm. Int J Cancer. 2011 Oct 15;129(8):2013-24. doi: 10.1002/ijc.26145. Epub 2011 Aug 8. Int J Cancer. 2011. PMID: 21520037 Free PMC article.
Bispecific antibody platforms for cancer immunotherapy.
Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ. Lameris R, et al. Among authors: van der vliet hj, van bergen en henegouwen pm. Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Crit Rev Oncol Hematol. 2014. PMID: 25195094 Review.
Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. J Immunol. 2017. PMID: 28416722 No abstract available.
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017. Oncoimmunology. 2017. PMID: 29296532 Free PMC article.
Multifaceted Activities of Seven Nanobodies against Complement C4b.
De la O Becerra KI, Oosterheert W, van den Bos RM, Xenaki KT, Lorent JH, Ruyken M, Schouten A, Rooijakkers SHM, van Bergen En Henegouwen PMP, Gros P. De la O Becerra KI, et al. Among authors: van bergen en henegouwen pmp. J Immunol. 2022 May 1;208(9):2207-2219. doi: 10.4049/jimmunol.2100647. Epub 2022 Apr 15. J Immunol. 2022. PMID: 35428691 Free PMC article.
144 results